{
  "id": "aaf75eb2472082a6",
  "title": "Incyte Announces European Commission Approval of Minjuvi ( tafasitamab ) for the Treatment of Relapsed or Refractory Follicular Lymphoma",
  "description": "20251217T164500Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2025-12/67258312-incyte-announces-european-commission-approval-of-minjuvi-tafasitamab-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma-004.htm",
  "published_at": "20251217T164500Z",
  "fetched_at": "2025-12-18T00:22:47.263985+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2025-12/67258312-incyte-announces-european-commission-approval-of-minjuvi-tafasitamab-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma-004.htm",
    "url_mobile": "",
    "title": "Incyte Announces European Commission Approval of Minjuvi ( tafasitamab ) for the Treatment of Relapsed or Refractory Follicular Lymphoma",
    "seendate": "20251217T164500Z",
    "socialimage": "https://www.finanznachrichten.de/chart-incyte-corporation-aktie-intraday-tradegate.png",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}